# RedChemExpress

## Product Data Sheet

### Bulevirtide

Cat. No.:	HY-P3465					
CAS No.:	2012558-47-1					
Molecular Formula:	C <sub>234</sub> H <sub>329</sub> N <sub>65</sub> O <sub>71</sub>					
Molecular Weight:	5398.86 (My1-GTNLSVPNPLGFFPDHQLDPAFGANSNNPDWOFNPNKDHWPEANKVG-NH2					
Sequence:	{Myr}-Gly-Thr-Asn-Leu-Ser-Val-Pro-Asn-Pro-Leu-Gly-Phe-Phe-Pro-Asp-His-Gln-Leu-As p-Pro-Ala-Phe-Gly-Ala-Asn-Ser-Asn-Asn-Pro-Asp-Trp-Asp-Phe-Asn-Pro-Asn-Lys-Asp-Hi s-Trp-Pro-Glu-Ala-Asn-Lys-Val-Gly-NH2					
Sequence Shortening:	{Myr}-GTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPNKDHWPEANKVG-NH2					
Target:	HBV					
Pathway:	Anti-infection					
Storage:	Sealed storage, away from moisture and light, under nitrogen					
	Powder -80°C 2 years -20°C 1 year					
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture					
	and light, under nitrogen)					

#### SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (9.26 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	0.1852 mL	0.9261 mL	1.8522 mL		
		5 mM	0.0370 mL	0.1852 mL	0.3704 mL		
		10 mM					
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (0.46 mM); Suspended solution; Need ultrasonic						
	2. Add each solvent o Solubility: ≥ 2.5 m	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (0.46 mM); Clear solution					

#### **BIOLOGICAL ACTIVITY**

Description

Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research<sup>[1][2]</sup>.

#### REFERENCES

[1]. Masetti C, et al. Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction. Liver Int. 2021 Jul;41(7):1441-1442.

[2]. Cheng D, et al. Clinical effects of NTCP-inhibitor myrcludex B. J Viral Hepat. 2021 Jun;28(6):852-858.

#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA